Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsKoji Sasaki, Jörge E. Cortes, Sara S. Strom et al.|The Lancet Haematology|2015Cited by 313
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Uria Mor et al.|Nature Medicine|2023Cited by 226
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) ‐ outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patientsShuangtao Zhao, Preetesh Jain, Rashmi Kanagal‐Shamanna et al.|American Journal of Hematology|2020Cited by 84
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell LymphomaPreetesh Jain, Michael Wang, Shuangtao Zhao et al.|Journal of Clinical Oncology|2021Cited by 82
Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational studyRosa Ruchlemer, Tamar Lachish, Ronen Ben‐Ami et al.|Mycoses|2019Cited by 80